TABLE 3.

Treatment history. All dosages are 20 mg/kg q2w unless otherwise specified.

Patient/Sex	Age at ERT initiation (y)	Time on alglucosidase (mo)	Age at ERT switch (y)	Time on avalglucosidase (mo)	Notes
1/F	57	30	59	19
2/F	42	121 (20 mg/kg q2w)	58	18
		23 (30 mg/kg q2w)
		37 (40 mg/kg q2w)
3/F	43	7	44	21
4/M	77	12 (20 mg/kg q2w)	82	23 (40 mg/kg q2w)	17 months VAL-1221 after 12 months on al
		1 (40 mg/kg q2w)
		33 (40 mg/kg q1w)
5/F	48	12	49	6 (5 mg/kg q2w)
				113 (20 mg/kg q2w)
6/F	71	72	77	16
7/F	67	12	68	41 (20 mg/kg q2w)
				19 (40 mg/kg q2w)
8/M	44	85 (20 mg/kg q2w)	53	16 (40 mg/kg q2w)
		24 (40 mg/kg q2w)
9/M	45	81 (20 mg/kg q2w)	58	12	21 months VAL-1221 after 81 months on al
		30 (20 mg/kg q2w)			16 months ACTUS-101 before switch
11/F	16	2.3	16	22
12/F	51	11	52	29 (20 mg/kg q2w)	3 months stopped ERT after 29 months on aval
				16 (20 mg/kg q2w)
13/F	7	175 (20 mg/kg q2w)	25	18 (40 mg/kg q2w)
		24 (40 mg/kg q2w)
		30 (40 mg/kg q1w)
14/M	46	9	47	17
15/M	2.5	75	9	21
16/M	2	146	14	10